BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17214336)

  • 1. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
    He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
    Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thymidine kinase 1 activity in breast cancer.
    Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
    Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
    He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
    Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
    Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
    Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
    He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
    Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can thymidine kinase levels in breast tumors predict disease recurrence?
    O'Neill KL; Hoper M; Odling-Smee GW
    J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
    Wang Z; Zhang W; Huo B; Dong L; Zhang J
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
    Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
    Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.
    Huang ZH; Tian XS; Li R; Wang XM; Wen W; Guan H; Yang YJ
    Exp Ther Med; 2012 Feb; 3(2):331-335. PubMed ID: 22969891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
    Tribukait B
    BMC Cancer; 2020 May; 20(1):440. PubMed ID: 32423477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
    Wu C; Yang R; Zhou J; Bao S; Zou L; Zhang P; Mao Y; Wu J; He Q
    J Immunol Methods; 2003 Jun; 277(1-2):157-69. PubMed ID: 12799048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast tumour thymidine kinase levels and disease recurrence.
    O'Neill KL; McKelvey VJ; Hoper M; Monteverde H; Odling-Smee GW; Logan H; Abram WP; McKenna PG
    Med Lab Sci; 1992 Dec; 49(4):244-7. PubMed ID: 1339926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
    Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
    Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
    Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
    Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.